<DOC>
	<DOCNO>NCT02222129</DOCNO>
	<brief_summary>A prospective , randomized comparison bupivacaine liposomal bupivacaine give local injection wound sit patient undergo robotic-assisted laparoscopic urologic surgery effort determine method reduce postoperative opioid use .</brief_summary>
	<brief_title>Efficacy Liposomal Bupivacaine Versus 0.25 % Bupivacaine Laparoscopic Urologic Surgery</brief_title>
	<detailed_description>Liposomal bupivacaine develop extend duration efficacy bupivacaine typical 6 - 8 hour 72 hour . The prolonged duration liposomal bupivacaine initially demonstrate mice 1994 . Two randomize control trial use liposomal bupivacaine bunionectomy hemorrhoidectomy result FDA approval use human . More recently , liposomal bupivacaine also find improve pain control patient undergoing total knee arthroplasty . Infiltration local anesthetic laparoscopic port sit common practice show study improve postoperative pain . To compare liposomal bupivacaine 0.25 % bupivacaine local analgesia follow laparoscopic robotic urologic surgery , randomize comparison-controlled trial perform .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>At least 18yearsold , undergo laparoscopic urologic surgery . Pregnant and/or nursing mother . Allergy bupivacaine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Randomized control trial</keyword>
	<keyword>anesthetics-local</keyword>
	<keyword>bupivacaine</keyword>
	<keyword>analgesia</keyword>
	<keyword>Pain , Postoperative</keyword>
</DOC>